Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting Peptide...

    2026-04-03

    Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting Peptide for Tumor and Angiogenesis Research

    Executive Summary: Cyclo (-RGDfC) is a cyclic RGD peptide that selectively binds integrin αvβ3, a receptor highly expressed in tumor cells and angiogenic vasculature (APExBIO, A8790). Its cyclic conformation confers enhanced stability and affinity over linear counterparts, supporting robust applications in cancer biology, drug delivery, and molecular imaging (AmericaPeptide 2023). The peptide is insoluble in water or ethanol but dissolves in DMSO at ≥49 mg/mL, enabling versatile conjugation workflows. Purity is routinely validated at ≥98% by HPLC, MS, and NMR. Storage at -20°C is required for optimal activity; solutions should be freshly prepared for each use. (APExBIO)

    Biological Rationale

    Integrins are transmembrane receptors that mediate cell adhesion, migration, and signaling in response to the extracellular matrix (ECM) (AmericaPeptide 2023). The αvβ3 integrin is overexpressed in multiple malignancies, including osteosarcoma, glioblastoma, and metastatic carcinomas (PeptideBridge 2023). This receptor is also a key regulator of angiogenesis, facilitating the formation of new blood vessels that supply nutrients to tumors and enable metastasis (ArotinololChem 2023). Cyclo (-RGDfC) mimics the native RGD motif found in ECM proteins such as fibronectin and vitronectin, allowing it to compete for αvβ3 binding sites and modulate integrin-mediated processes. Targeting αvβ3 with high-affinity cyclic RGD peptides supports applications in tumor imaging, cell migration studies, and anti-angiogenesis strategies. This article extends previous analyses by offering quantitative, mechanistic details and updated best practices for deploying Cyclo (-RGDfC) in advanced research workflows.

    Mechanism of Action of Cyclo (-RGDfC)

    Cyclo (-RGDfC) is a cyclic pentapeptide with the sequence c(RGDfC), where 'f' denotes D-phenylalanine and 'C' forms a disulfide bridge, stabilizing the ring structure (APExBIO). This conformation restricts flexibility, increasing binding specificity for αvβ3 integrin over other RGD-binding integrins (e.g., αvβ5, α5β1). Upon binding, Cyclo (-RGDfC) sterically blocks the ligand-binding domain of αvβ3, preventing ECM protein engagement and downstream signaling. This inhibition alters cell adhesion, migration, and survival pathways, especially in tumor and endothelial cells. The peptide can also be conjugated to fluorophores, drugs, or nanoparticles, enabling site-specific delivery and visualization in αvβ3-positive tissues (AmericaPeptide 2023).

    Evidence & Benchmarks

    • Cyclo (-RGDfC) binds integrin αvβ3 with nanomolar affinity, outperforming linear RGD peptides in selectivity and serum stability (PeptideBridge 2023).
    • In canine osteosarcoma models, αvβ3 expression is correlated with metastatic potential and poor prognosis (Royals et al., AJVR 2005).
    • Cyclo (-RGDfC) enables high-throughput angiogenesis and cell adhesion assays in hydrogel platforms, facilitating reproducible integrin signaling studies (Cyclo-RGDfK.com 2023).
    • Peptide is stable at -20°C for months; DMSO solutions (≥49 mg/mL) retain functional activity for at least 24 hours at 4°C (APExBIO).
    • Conjugation to imaging agents or drugs does not significantly affect αvβ3 binding, provided the RGD motif remains accessible (AmericaPeptide 2023).

    Applications, Limits & Misconceptions

    • Integrin-mediated cell adhesion and migration assays: Cyclo (-RGDfC) is used to dissect αvβ3-dependent signaling pathways in cancer and endothelial cells (ArotinololChem 2023).
    • Targeted drug delivery: Peptide conjugates enhance selective delivery of cytotoxics or nanoparticles to αvβ3-positive tumors (AmericaPeptide 2023).
    • Molecular imaging: Cyclo (-RGDfC) labeled with fluorophores or radioisotopes enables noninvasive detection of angiogenic or metastatic lesions (PeptideBridge 2023).
    • High-throughput biomaterials: Functionalization of hydrogels with Cyclo (-RGDfC) supports spatially programmable cell culture and tissue engineering (Cyclo-RGDfK.com 2023).

    Common Pitfalls or Misconceptions

    • Cyclo (-RGDfC) is insoluble in water or ethanol; attempts to dissolve in these solvents result in precipitation and loss of activity (APExBIO).
    • Not all tumor types overexpress αvβ3; efficacy as a targeting ligand is context-dependent (PeptideBridge 2023).
    • Long-term storage in solution leads to hydrolysis and loss of function; always prepare fresh DMSO stocks for critical assays (APExBIO).
    • Linear RGD peptides or scrambled controls do not recapitulate the specificity or stability of Cyclo (-RGDfC) (AmericaPeptide 2023).
    • Conjugation chemistry must preserve the RGD motif's accessibility for effective αvβ3 binding (AmericaPeptide 2023).

    Workflow Integration & Parameters

    For optimal results, Cyclo (-RGDfC) (A8790, APExBIO) should be dissolved in DMSO at concentrations ≥49 mg/mL and stored at -20°C (product page). Working solutions should be diluted into assay buffer immediately before use; avoid freeze-thaw cycles. For integrin-mediated cell adhesion assays, typical working concentrations range from 0.1 to 10 μM, depending on cell type and endpoint (AmericaPeptide 2023). For conjugation, standard peptide coupling chemistries (e.g., maleimide-thiol or NHS-ester) are compatible, provided the RGD motif remains unmodified. Quality control includes HPLC, MS, and NMR analysis, with ≥98% purity expected. For large-scale or translational workflows, refer to best practices outlined in this review (which also benchmarks Cyclo (-RGDfC) against emerging alternatives and provides guidance on hydrogel functionalization not detailed here).

    Conclusion & Outlook

    Cyclo (-RGDfC) is a gold-standard cyclic RGD peptide for selective αvβ3 integrin targeting across cancer, angiogenesis, and biomaterials research. Its robust stability, high specificity, and chemical versatility enable advanced applications in targeted imaging, drug delivery, and integrin-mediated cell signaling studies. Researchers should adhere to recommended storage and handling protocols for reproducible results. For further insights into advanced biomaterial integration and translational strategies, see the contrast with spatially programmable hydrogel methodologies in this article, which focuses on high-throughput 3D models, an aspect only briefly summarized in the present review. APExBIO continues to provide high-purity, validated Cyclo (-RGDfC) (A8790) to support innovation in tumor targeting and integrin biology.